Blog

Ideas, analysis and perspectives on leadership, communication and business results.

Novo Nordisk concludes Catalent acquisition and strengthens its commitment to Wegovy

Novo Nordisk completes the acquisition of Catalent for 10.659 billion euros. The operation includes three new plants to boost Wegovy production and.

Chronic GVHD: A Silent Challenge for Bone Marrow Transplant Recipients

Discover chronic GVHD, a little-known disease that affects many bone marrow transplant recipients. Learn about its symptoms and the importance of awareness.

Neuralink Explores Robotic Arm Control with Brain Implants

Neuralink launches the CONVOY trial to test robotic arm control through brain implants.

Amgen faces disappointment in MariTide clinical trial, its weight loss drug

Amgen's MariTide clinical trial results disappoint, with 20% weight loss and higher dropout rate compared to competitors like.

Trump Appoints Robert Kennedy Jr. as Secretary of Health and Human Services

Donald Trump appoints Robert F. Kennedy Jr. as Secretary of Health and Human Services

Medical Devices Diploma 2025: Innovation and Professionalization in the Health Sector

Medical Devices Diploma 2025: Specialized training endorsed by UNAM and CANIFARMA. Virtual, flexible and certified modality.

Virtual Twins: Dassault Systèmes' Revolution in Clinical Trials

Discover how virtual twins are revolutionizing clinical trials. Dassault Systèmes launches the ENRICHMENT Playbook,

Novo Nordisk warns about risks of unregulated copies of weight loss medications

Novo Nordisk alerts about 10 deaths and 100 hospitalizations from unregulated copies of its Ozempic and Wegovy medications

Neuralink receives green light for clinical trials in Canada: a revolutionary breakthrough in neurotechnology

Elon Musk's Neuralink begins its first clinical trial in Canada to test a brain implant that will allow people with quadriplegia to control.

DSO: Bayer and its bold transformation: from traditional management to self-management

Discover how Bayer, with over 160 years of history and 100,000 employees, is transforming its traditional management model with Dynamic Shared Ownership.

United States Finances Obesity Medications from Novo Nordisk and Lilly

The U.S. will finance obesity medications from Novo Nordisk and Lilly under Medicaid, benefiting 24.2 million people.

Vesalius and GSK Join Forces to Develop Innovative Parkinson's Treatments

Vesalius and GSK announce a strategic alliance to develop innovative treatments against Parkinson's disease and neurodegenerative diseases

← Previous4 / 29Next →